Metabolomic Profiling of Aqueous Humor from Pathological Myopia Patients with Choroidal Neovascularization.
aqueous humor
carbohydrate metabolism
choroidal neovascularization
glycometabolism
metabolomics
pathological myopia
Journal
Metabolites
ISSN: 2218-1989
Titre abrégé: Metabolites
Pays: Switzerland
ID NLM: 101578790
Informations de publication
Date de publication:
30 Jul 2023
30 Jul 2023
Historique:
received:
05
06
2023
revised:
27
07
2023
accepted:
28
07
2023
medline:
25
8
2023
pubmed:
25
8
2023
entrez:
25
8
2023
Statut:
epublish
Résumé
Choroidal neovascularization (CNV) is a severe complication observed in individuals with pathological myopia (PM). Our hypothesis is that specific metabolic alterations occur during the development of CNV in patients with PM. To investigate this, an untargeted metabolomics analysis was conducted using gas chromatography-mass spectrometry (GC-MS) and liquid chromatography-mass spectrometry (LC-MS) on aqueous humor (AH) samples obtained from meticulously matched PM patients, including those with CNV (n = 11) and without CNV (n = 11). The analysis aimed to identify differentially expressed metabolites between the two groups. Furthermore, the discriminative ability of each metabolite was evaluated using the area under the receiver operating characteristic curve (AUC). Enriched metabolic pathways were determined using the KEGG and MetaboAnalyst databases. Our results revealed the detection of 272 metabolites using GC-MS and 1457 metabolites using LC-MS in AH samples. Among them, 97 metabolites exhibited significant differential expression between the CNV and non-CNV groups. Noteworthy candidates, including D-citramalic acid, biphenyl, and isoleucylproline, demonstrated high AUC values ranging from 0.801 to 1, indicating their potential as disease biomarkers. Additionally, all three metabolites showed a strong association with retinal cystoid edema in CNV patients. Furthermore, the study identified 12 altered metabolic pathways, with five of them related to carbohydrate metabolism, suggesting their involvement in the occurrence of myopic CNV. These findings provide possible disease-specific biomarkers of CNV in PM and suggest the role of disturbed carbohydrate metabolism in its pathogenesis. Larger studies are needed to validate these findings.
Identifiants
pubmed: 37623844
pii: metabo13080900
doi: 10.3390/metabo13080900
pmc: PMC10456621
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : National Natural Science Foundation of China
ID : 81770944
Organisme : Foundation for the Shanghai Key Laboratory of Visual Impairment and Restoration
ID : 12DZ2260500
Organisme : Key NHC Key Laboratory of Myopia(Fudan University); Laboratory of Myopia, Chinese Academy of Medical Sciences
ID : none
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
J Biol Chem. 2019 Jun 28;294(26):10278-10289
pubmed: 31110046
Cell. 2002 Mar 8;108(5):705-15
pubmed: 11893340
Biochem Soc Trans. 2017 Oct 15;45(5):1105-1115
pubmed: 28900017
Front Pharmacol. 2022 Nov 14;13:964475
pubmed: 36452230
Nucleic Acids Res. 2014 Jan;42(Database issue):D199-205
pubmed: 24214961
Ophthalmology. 2003 Jul;110(7):1297-305
pubmed: 12867382
Clin Exp Ophthalmol. 2022 Dec;50(9):1065-1081
pubmed: 35849327
Exp Mol Med. 2015 Feb 20;47:e142
pubmed: 25697147
BMC Ophthalmol. 2018 Feb 27;18(1):63
pubmed: 29486760
BMC Microbiol. 2021 Nov 4;21(1):305
pubmed: 34736405
Alcohol Clin Exp Res. 1993 Apr;17(2):268-71
pubmed: 8488966
Nucleic Acids Res. 2018 Jul 2;46(W1):W486-W494
pubmed: 29762782
Invest Ophthalmol Vis Sci. 2020 Dec 1;61(14):13
pubmed: 33315052
J Chromatogr B Analyt Technol Biomed Life Sci. 2019 Nov 1;1130-1131:121822
pubmed: 31669633
Int J Mol Sci. 2017 Dec 21;19(1):
pubmed: 29267192
Biomed Res Int. 2021 Feb 9;2021:8885032
pubmed: 33628826
Environ Pollut. 2023 Jan 15;317:120811
pubmed: 36470458
Exp Eye Res. 2017 Jun;159:147-155
pubmed: 28322828
J Physiol. 2006 Oct 15;576(Pt 2):391-401
pubmed: 16873409
Invest Ophthalmol Vis Sci. 2017 May 1;58(6):BIO88-BIO98
pubmed: 28525563
Food Funct. 2022 May 10;13(9):5229-5239
pubmed: 35438708
Handb Exp Pharmacol. 2013;(215):57-76
pubmed: 23579449
J Antibiot (Tokyo). 2012 Mar;65(3):153-156
pubmed: 22293916
Prog Retin Eye Res. 2012 Sep;31(5):495-525
pubmed: 22569156
Drug Discov Today. 2019 Sep;24(9):1735-1748
pubmed: 31158511
Clin Chem. 1995 Aug;41(8 Pt 1):1094-104
pubmed: 7628083
Exp Eye Res. 2022 Sep;222:109184
pubmed: 35820467
J Clin Med. 2020 Oct 28;9(11):
pubmed: 33126435
Eye (Lond). 2023 Feb 25;:
pubmed: 36841867
Int Immunopharmacol. 2011 Sep;11(9):1341-7
pubmed: 21575742
Eye (Lond). 2023 Mar;37(4):670-677
pubmed: 35322213
J Proteome Res. 2020 Feb 7;19(2):699-707
pubmed: 31755721
Eye (Lond). 2021 Mar;35(3):817-824
pubmed: 32424328
Clin Chem. 1990 Mar;36(3):474-6
pubmed: 2311216
J Med Chem. 2022 Aug 11;65(15):10471-10480
pubmed: 35857416
J Pharm Biomed Anal. 2016 Aug 5;127:18-25
pubmed: 27036676
Front Pharmacol. 2022 Aug 30;13:952337
pubmed: 36120368
Cytokine. 2021 Jan;137:155308
pubmed: 33128924
Mol Cell Biochem. 2018 Nov;448(1-2):27-41
pubmed: 29388153
Am J Ophthalmol. 2014 Jan;157(1):9-25.e12
pubmed: 24099276
Prog Retin Eye Res. 2018 Mar;63:92-106
pubmed: 29111299